Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

Article ID	Journal	Published Year	Pages	File Type
10137653	Pharmacological Research	2018	23 Pages	PDF

Keywords

BRAF MEKi BRAFi CTLA-4 TIDs Immunological effects PD-L2 IRAE MDSCs Tregs IFNγ DLT ATC CCL2 PD-1 ORR PD-L1 PFs Human leukocyte antigen HLA immunotherapy progression-free survival overall survival Tim-3 Melanoma Targeted therapy dose-limiting toxicities Dendritic cells Myeloid-derived suppressor cells Regulatory T cells Immune-related adverse events LDH chemokine ligand 2 MEK Programmed cell death 1 ligand 1 BRAF inhibitors MEK inhibitors cytotoxic T-lymphocyte-associated protein 4 programmed cell death protein 1 Interferon gamma

Related Topics

Health Sciences Pharmacology, Toxicology and Pharmaceutical Science Pharmacology

Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy

Authors

Marvin Kuske, Dana Westphal, Rebekka Wehner, Marc Schmitz, Stefan Beissert, Christian Praetorius, Friedegund Meier,